The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with AUD and ALD hepatology clinics. There are many benefits of AUD treatment among patients with AUD and ALD such as reduction in liver-related complications and hepatology clinicians providing this care in an integrated fashion can help more patients have access to it.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
30
A multipronged intervention including hepatology clinician education, patient education, clinical decision support, and clinician audit and feedback which will be adapted and tested.
Yale School of Medicine/Yale-New Haven Health
New Haven, Connecticut, United States
Recruitment success to assess Feasibility
Percentage of clinicians enrolled out of all recruited
Time frame: 3, 6 and 12 months
Educational Workshop Attendance to assess Feasibility
Percentage of clinicians that attend the educational workshops
Time frame: 3, 6 and 12 months
Clinician Decision Support Tool Use to assess Feasibility
Percentage of visits involving patients with AUD and ALD in which the clinical decision support tool is used
Time frame: 3, 6 and 12 months
Acceptability of Intervention Measure (AIM) to assess Acceptability
4-item measure of perceived intervention acceptability. Total score 1-5 with higher scores indicating greater acceptability
Time frame: 3, 6 and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.